Conv. Plasma
Nigella Sativa
Nitric Oxide
Peg.. Lambda

Home   COVID-19 treatment studies for Hydroxychloroquine  COVID-19 treatment studies for HCQ  C19 studies: HCQ  HCQ   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Hospitalization time 18% Improvement Relative Risk Alqassieh et al. HCQ for COVID-19 LATE TREATMENT Is late treatment with HCQ beneficial for COVID-19? Prospective study of 131 patients in Jordan Shorter hospitalization with HCQ (not stat. sig., p=0.11) Alqassieh et al., F1000Research, Preprint Favors HCQ Favors control
Clinical characteristics and predictors of the duration of hospital stay in COVID-19 patients in Jordan
Alqassieh et al., F1000Research, Preprint (Preprint)
Alqassieh et al., Clinical characteristics and predictors of the duration of hospital stay in COVID-19 patients in Jordan, F1000Research, Preprint (Preprint)
Dec 2020   Source   PDF  
  All Studies   Meta
Prospective observational study of 131 COVID-19 patients in Jordan, showing 18% shorter hospital stay with HCQ, p = 0.11.
hospitalization time, 18.2% lower, relative time 0.82, p = 0.11, treatment 63, control 68.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Alqassieh et al., 10 Dec 2020, prospective, Jordan, preprint, 10 authors.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperHCQAll
Abstract: F1000Research 2020, 9:1439 Last updated: 07 JAN 2022 RESEARCH ARTICLE Clinical characteristics and predictors of the duration of hospital stay in COVID-19 patients in Jordan [version 1; peer review: 1 approved with reservations, 1 not approved] Rami S. Alqassieh 1,2, Isam K. Bsisu 3, Mohammed Qussay Al-Sabbagh Naser M. El-Hammuri2,5, Moh’d A. Yousef 3, Mohammad A. El Jarbeh 3, Ahmed A. Sharqawi 3, Heba Z. Smadi3, Sami A. Abu-Halaweh3, Mohammad M. Abufaraj6,7 4, 1Cardiac Anesthesia Division, Department of Anesthesia and Intensive care, Prince Hamza Hospital, Amman, Jordan 2Faculty of Medicine, Hashemite University, Zarqa, Jordan 3Department of Anesthesia and Intensive Care, School of medicine, The University of Jordan, Amman, Jordan 4School of Medicine, The University of jordan, Amman, Jordan 5Department of Surgery, Prince Hamza Hospital, Amman, Jordan 6Division of Urology, Department of Special Surgery, School of Medicine, The University of Jordan, Amman, Jordan 7Department of Urology, Medical University of Vienna, Vienna, Austria v1 First published: 10 Dec 2020, 9:1439 Open Peer Review Latest published: 10 Dec 2020, 9:1439 Reviewer Status Abstract Background: On March 11th, 2020, the World Health Organization (WHO) declared coronavirus disease 2019 (COVID-19) as a global pandemic. Healthcare systems in low- and middle-income countries may face serious limitations during a pandemic, for which understanding the predictors of prolonged hospital stay are crucial in decreasing the mortality rate. The aim of this study was to investigate the predictors of increased length of hospitalization among COVID-19 patients. Methods: In this prospective study, we investigated the effect of presenting symptoms and laboratory investigations on the duration of hospitalization of 131 COVID-19 patients at a tertiary hospital in Jordan from March 17th to April 9th, 2020. Results: Patients median age was 24 years [interquartile range (IQR): 8-39], of which 67 (51.15%) were males and 64 (48.85%) were females. Smokers had shorter in-hospital stay (OR: -3.52; 95% CI: -6.73 to -0.32; P=0.03). Taste loss (OR: 5.1; 95% CI: 1.95 to 8.25; P<0.01) and chills or rigors (OR: 4.08; 95% CI: 0.73 to 7.43; P=0.02) were the symptoms significantly associated with increased in-hospital stay, while those who had malaise (OR: -4.98; 95% CI: -8.42 to -1.59; P<0.01) and high white blood cell (WBC) count (OR: -0.74; 95% CI: -1.31 to -0.17; P=0.01) had faster recovery. Conclusions: Our study found that the most common presenting Invited Reviewers version 1 10 Dec 2020 1 2 report report 1. Denise Battaglini , San Martino Policlinico Hospital, Genoa, Italy 2. Omar Soliman Mohamed El-Masry , Imam Abdulrahman Bin Faisal University, Dammam, Saudi Arabia Any reports and responses or comments on the article can be found at the end of the article. Page 1 of 13 F1000Research 2020, 9:1439 Last updated: 07 JAN 2022 symptoms of COVID-19 are cough, malaise, and headache. Smoking, presenting with malaise or elevated WBCs were associated with shorter hospital stay, while loss of taste and chills or rigors at presentation were associated with a longer in-hospital stay. Keywords COVID-19, SARS-CoV-2, symptoms, smoking, Hydroxychloroquine. This article is included in the Emerging Diseases and Outbreaks gateway. This article is included in the Coronavirus collection. Corresponding..
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop